SCHEMBL153103

SCHEMBL153103

O=S(=O)(O)OCCS

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Guanidine SCHEMBL27561077 0.88 PTGS1 (0.33)
SCHEMBL17183009 0.83
SCHEMBL28505751 0.81 FNTA (0.39)
SCHEMBL562188 0.81 CA2 (0.44)
SCHEMBL17183004 0.79 FNTA (0.46)
SCHEMBL17183010 0.79 FNTA (0.46)
SCHEMBL3655506 0.79 FNTA (0.46)
Ammonia Solution, Strong SCHEMBL1552139 0.78 CA2 (0.41)
SCHEMBL17456450 0.78 CA2 (0.41)
SCHEMBL3640927 0.75 CA2 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119060256-A Preparation method of salt-tolerant strong cation exchange chromatography medium 北京石油化工学院 2024-12-03 CN claimed
CN-108070009-B Method for preparing DNA coding compound library and initial fragment compound and prepared DNA coding compound 上海药明康德新药开发有限公司 2021-04-13 CN claimed
US-7910568-B2 Inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, gastrointestinal disorders; prevention/treatment of colon cancer; releases hydrogen sulfide ANTIBE THERAPEUTICS INC. (CA) 2011-03-22 US claimed
US-20090233886-A1 DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID ANTIBE THERAPEUTICS INC. (CA) 2009-09-17 US claimed
US-20080207564-A1 Derivaitves of 4-Or 5-Aminosalicylic Acid ANTIBE THERAPEUTICS INC. (CA) 2008-08-28 US claimed
EP-1883645-A4 DERIVATIVES OF 4-OR 5-AMINOSALICYLIC ACID ANTIBE THERAPEUTICS INC (US) 2008-06-25 EP claimed
EP-1883645-A1 DERIVATIVES OF 4-OR 5-AMINOSALICYLIC ACID Antibe Therapeutics Inc. (US) 2008-02-06 EP claimed
US-20070197479-A1 Derivatives of 4- or 5-aminosalicylic acid ANTIBE THERAPEUTICS INC. (CA) 2007-08-23 US claimed
WO-2006125295-A1 DERIVATIVES OF 4-OR 5-AMINOSALICYLIC ACID ANTIBE THERAPEUTICS INC. (CA) 2006-11-30 WO claimed
US-20060270635-A1 Derivatives of 4- or 5-aminosalicylic acid ANTIBE THERAPEUTICS INC. (CA) 2006-11-30 US claimed
WO-2006125293-A1 DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID ANTIBE THERAPEUTICS INC. (CA) 2006-11-30 WO claimed
US-4051314-A FROM FUNGUS OF CLASS BASIDIOMYCETES, ANTICANCER AGENTS KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JA) 1977-09-27 US claimed
CN-119060256-A Preparation method of salt-tolerant strong cation exchange chromatography medium 北京石油化工学院 2024-12-03 CN disclosed
CN-111417735-B Copper fine particle sintered body DIC株式会社 2022-10-04 CN disclosed
CN-108070009-B Method for preparing DNA coding compound library and initial fragment compound and prepared DNA coding compound 上海药明康德新药开发有限公司 2021-04-13 CN disclosed
EP-2762485-B1 METHOD FOR PRODUCING POLYPEPTIDE FRAGMENT WITH HIGH EFFICIENCY, WHICH IS SUITABLE FOR NCL METHOD GLYTECH INC (JP) 2018-08-01 EP disclosed
EP-0295955-A2 Lectins and antiretroviral drugs containing the lectins as active ingredients KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1988-12-21 EP disclosed
EP-0295962-A2 Protein-polysaccharide for treating retroviral infections KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1988-12-21 EP disclosed
EP-0295956-A2 Use of a protein-bound polysaccharide for making a drug for treating AIDS. KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1988-12-21 EP disclosed
US-4051314-A FROM FUNGUS OF CLASS BASIDIOMYCETES, ANTICANCER AGENTS KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JA) 1977-09-27 US disclosed